10-year pharmaceutical distribution agreement under which we distribute branded and generic pharmaceutical products to Walgreens pharmacies (US PVA)
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Robert P. Mauch
Also a director
President and Chief Executive Officer
|
58 |
Since 2024
2 years
|
$18,256,227 | |
|
Eva C. Boratto
Chief Financial Officer
Title from the Form 4 dated Nov 11, 2026
|
Not stated | Not stated | Not reported | |
|
Elizabeth S. Campbell
Executive Vice President and Chief Legal Officer
|
51 |
Since 2021
5 years
|
$5,176,668 | |
|
Pawan Verma
EVP, Chief Data & Info Officer
Title from the Form 4 dated Nov 11, 2026
|
49 | Not stated | Not reported | |
|
Lazarus Krikorian
SVP & Chief Accounting Officer
Title from the Form 4 dated Nov 11, 2026
|
Not stated | Not stated | Not reported | |
|
Samantha L. Hammock
Executive Vice President and Chief Human Resources Officer
|
Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Jan 22, 2026 · updated by the 8-Ks of Aug 14, 2026 and Sep 25, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
D. Mark Durcan
Board chair
|
64 |
2015
11 years
|
Independent |
Executive · Chair
|
ASML Holding N.V. (Nasdaq: ASML) | $375,217 | |
|
Robert P. Mauch
CEO
|
59 |
2024
2 years
|
Not independent |
Executive
|
None stated | Paid as CEO | |
|
Werner Baumann
|
63 |
2023
3 years
|
Independent |
Audit · Chair
Compensation and Succession Planning
Executive
Special Litigation · Chair
|
None stated | $383,095 | |
|
Frank K. Clyburn
|
61 |
2024
2 years
|
Independent |
Compliance and Risk
Finance
|
Revolution Medicines, Inc. (Nasdaq: RVMD) | $396,436 | |
|
Ellen G. Cooper
|
61 |
2026
this year
|
Independent | None stated | Lincoln National Corporation (NYSE: LNC) | Not stated | |
|
Lon R. Greenberg
|
75 |
2013
13 years
|
Independent |
Compliance and Risk
Executive
Finance
Governance, Sustainability and Corporate Responsibility · Chair
|
None stated | $330,225 | |
|
Redonda G. Miller, M.D.
|
59 |
2023
3 years
|
Independent |
Compliance and Risk · Chair
Executive
Governance, Sustainability and Corporate Responsibility
Special Litigation
|
None stated | $385,225 | |
|
Dennis M. Nally
|
73 |
2020
6 years
|
Independent |
Audit
Compensation and Succession Planning · Chair
Executive
|
Morgan Stanley (NYSE: MS) | $345,706 | |
|
Lori J. Ryerkerk
|
63 |
2025
1 year
|
Independent | None stated | Eaton Corporation (NYSE: ETN), Norfolk Southern Corp (NYSE: NSC) | $192,390 | |
|
Lauren M. Tyler
|
64 |
2023
3 years
|
Independent |
Audit
Governance, Sustainability and Corporate Responsibility
Special Litigation
|
None stated | $360,940 | |
|
Robert E. Sanchez
Joined Oct 1, 2026
|
- | - | - | - | - | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
10-year pharmaceutical distribution agreement under which we distribute branded and generic pharmaceutical products to Walgreens pharmacies (US PVA)
Generics purchasing services arrangement providing access to generics and related products through a global sourcing arrangement (WBAD Arrangement)
Board seat designated by WBA under the Shareholders Agreement; Ms. Barra served as a director until May 27, 2025
Acquisition of a majority of WBA's Alliance Healthcare businesses for cash plus two million shares of our Common Stock, subject to purchase price adjustments
Extension of the US PVA and the WBAD Arrangement by three years through 2029
Distribution agreement to supply branded and generic pharmaceutical products to WBA's Boots pharmacies in the United Kingdom
Loading...